Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging AUSTIN, Texas / Jul 26, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncology highlighting the utility of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, for surveillance in Merkel... Read more
CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, has conducted an operations review and announces that it intends to transition to a capital light operations model – which is anticipated to result in an immediate material reduction in operating costs. This capital light... Read more
SAN DIEGO / Jul 25, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024.
Second Quarter 2024 Financial Highlights: Revenue grew 15% year-over-year to $1.004 billion on a reported basis and 16% year-over-year on an organic1 basis.
U.S. revenue grew 19% and international revenue grew 7% on a reported basis and 10% on an organic1 basis, all on a year-over-year basis.
GAAP operating income... Read more
Indus Group Consumes Approximately 450 Million Pounds of Cotton Annually for the Manufacture of Apparel, Footwear, and Accessories for Global Brands and Retailers STONY BROOK, NY / ACCESSWIRE / July 25, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the signing of a five-year license and commercialization agreement for its CertainT® traceability platform (the "Agreement") with... Read more
NEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to note that a small contributing factor to the cash increase was the incoming cash collections that were expected in Q1, but were delayed and received in Q2 due to the impact of the Change Healthcare... Read more
BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today announced significant improvements to its ColoAlert product, currently being commercialized across Europe and in select international markets. These updates aim to enhance customer satisfaction and streamline lab operations.
ColoAlert is a highly efficacious and easy-to-use, at-home... Read more
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve detection, risk reduction, and care. While recent developments in tumor genetic... Read more
Highlights Net business wins in the quarter of $2,579 million, an increase of 6.6% on quarter two 2023. Reflects a net book to bill in the quarter of 1.22, and a trailing twelve month net book to bill of 1.24. Closing backlog of $23.8 billion, an increase of 2.0% on quarter one 2024 and 9.9% on quarter two 2023. Quarter two revenue of $2,120.2 million representing an increase of 4.9% on prior year revenue and 5.3% on a constant currency basis. Quarter two... Read more
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics
Under the agreement, Charles River will make an equity investment in Autobahn Labs
Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn’s Board of Directors WILMINGTON, Mass. & SAN FRANCISCO / Jul 24, 2024 / Business... Read more
WALTHAM, Mass. / Jul 24, 2024 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024.
Second Quarter 2024 Highlights Second quarter revenue was $10.54 billion.
Second quarter GAAP diluted earnings per share (EPS) increased 15% to $4.04.
Second quarter adjusted EPS increased 4% to $5.37. Advanced our proven growth strategy, launching a range... Read more
MENLO PARK, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that Novogene is using its Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany, serving customers across the European scientific community. Novogene is a leading provider of genomic services and bioinformatics expertise, working with a wide range of leading research... Read more
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity
Upgraded test covered by Medicare and major private payers for comprehensive genomic profiling of all advanced solid tumors PALO ALTO, Calif. / Jul 23, 2024 / Business Wire / Guardant Health, Inc. (NASDAQ:GH),... Read more
SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of the first multi-site study in multiple myeloma (MM) comparing optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs).
Multiple myeloma is a type of blood cancer originating in the plasma cell, known as a plasma cell neoplasm (PCN), and though... Read more
News Summary: Reduces sample volume requirements by 25x through use of advanced microfluidic technologies while increasing throughput up to 24x compared with competitor capillary DSC technologiesi.
Streamlines thermal stability testing of biologics using disposable microfluidic chips (MFCs) enabling analysis under actual high-concentration drug dosing and use conditions.
Delivers faster and more accurate measurements of high-concentration biological drug formulationsii... Read more
Second quarter revenues of $2.40 billion, up 2.5% from 2023
Second quarter reported diluted earnings per share ("EPS") of $2.03, down 1.0% from 2023; and adjusted diluted EPS of $2.35, up 2.2% from 2023
Full year 2024 revenues now expected to be between $9.50 billion and $9.58 billion; reported diluted EPS now expected to be between $7.57 and $7.77; and adjusted diluted EPS expected to be between $8.80 and $9.00 SECAUCUS, N.J., July 23, 2024 /PRNewswire/ -- Quest... Read more
WASHINGTON, July 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 28, 2024. All results in this release reflect only continuing operations unless otherwise noted.
Key Second Quarter 2024 Results Net earnings were $907 million, or $1.22 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.72.
Revenues decreased 3.0% year-over-year to $5.7 billion... Read more
Revenue of $528.1 million in the second quarter of 2024 increased 14.6% from revenue of $460.9 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%.
Net new business awards were $551.0 million in the second quarter of 2024, representing a decrease of 4.1% from net new business awards of $574.8 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x.
Second quarter of 2024 GAAP net income... Read more
Expands Agilent’s end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing SANTA CLARA, Calif. / Jul 22, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million.
Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and... Read more
MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that Aetna has updated its TMS (transcranial magnetic stimulation) coverage to include adolescents aged 15 and older with MDD (major depressive disorder). This expanded access follows the recent clearance from the... Read more
Revenue of $3,814 million
GAAP Net Income of $363 million, Adjusted EBITDA of $887 million
GAAP Diluted Earnings per Share of $1.97, Adjusted Diluted Earnings per Share of $2.64
R&D Solutions quarterly bookings of $2.7 billion, representing a book-to-bill ratio of 1.27x
R&D Solutions contracted backlog of $30.6 billion, up 7.7 percent reported and 8.1 percent at constant currency year-over-year
Full-year 2024 guidance updated for revenue to be between $15,425... Read more
TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX:EDT) (the "Company" or "Spectral") is pleased to announce the closing of an additional non-brokered offering of US$1 million of 9% convertible notes of the Company (the “Notes”) at a price of US$1,000 per convertible note due on May 1, 2028 (the “Offering”).
The Notes were sold to one of the Company’s largest shareholders pursuant to the exercise of their anti-dilution pre-emptive rights relating... Read more
SAN DIEGO, July 18, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24, the company will present a Strategy Update on Tuesday, August 13, 2024 starting at 8:00am Pacific Time. The event will feature presentations by members of Illumina's executive team and conclude with a Q&A session.
Webcast Details
The webcast can be accessed through the Events & Presentations section of Illumina's Investor Relations website at i... Read more
STONY BROOK, NY / ACCESSWIRE / July 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that the U.S. Defense Logistics Agency (DLA) exercised the first one-year option period of a three-year base contract with two one-year option periods entered into in May 2021. The contract supports DLA's counterfeit mitigation initiatives and product verification and testing programs specific to FSC 5962 microcircuits.... Read more
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors SOUTH SAN FRANCISCO, Calif. / Jul 18, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the first patient has been dosed in Pure Biologics’ exploratory Phase 0 clinical study of PBA-0405. PBA-0405 is a... Read more
PALO ALTO, Calif. / Jul 18, 2024 / Business Wire / Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.
“Dr. Hidalgo brings a wealth of expertise and leadership in translational... Read more
NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago.
Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division’s revenues will reach more than $1.5 million per... Read more
DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.
Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof. WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), a global science... Read more
VANCOUVER, BC / ACCESSWIRE / July 17, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that it has signed a statement of work ("SOW") with a German-based international contract research, development, and manufacturing organization (the "CRDMO"). The SOW is focused on the Company's flagship Cladribine oral dissolvable film ("ODF") development program.
The SOW sets out a number of important deliverables, including... Read more
Available Today for Life Science Research Use Only CHICAGO / Jul 16, 2024 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology... Read more
Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets NEW YORK, July 16, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s to employees beginning in the third quarter of 2024.
The employer, a leader... Read more
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. The webcast was recorded and can be viewed at... Read more
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early detection of hard-to-detect and treat cancers, is pleased to announce today that long time collaborators at the University of Manitoba Therapeutics will be presenting this week compelling new research findings on glioblastoma at the 2024 Globalization... Read more
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acquisition of Meilleur Technologies, Inc., which includes NAV-4694, expanding Lantheus’ Alzheimer’s disease pipeline.
Through this acquisition, Lantheus now has the worldwide exclusive... Read more
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company’s freedom to operate in the MRD market and broadens patient access to... Read more
MALVERN, Pa., July 11, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that California Medicaid (Medi-Cal) has added TMS (transcranial magnetic stimulation) coverage for adults and adolescents aged 15 and older with MDD (major depressive disorder). This is the first policy from Medi-Cal... Read more
myeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing to Quickly Match Patients with Appropriate Trials Across North America WALTHAM, Mass. / Jul 11, 2024 / Business Wire / To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is partnering with the National Cancer Institute (NCI) – part of the National... Read more
Preliminary OvaWatch® volume during Q2 2024 grew 24% over the prior quarter to 1,307 units
Preliminary OvaSuiteSM volume during Q2 2024 grew 11% over the prior quarter to 6,471 units AUSTIN, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced preliminary second quarter... Read more
Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs.
Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies.
New technology will work to capture and analyze the highly heterogeneous tumor microenvironment. WASHINGTON, July 11, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today launched a research co... Read more
CHICAGO / Jul 10, 2024 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has reached a research milestone of over 500 research publications. In the last eight years, Tempus has invested in rigorous scientific research to validate its diagnostic offerings, while also working with biopharma and academic collaborators to publish research supported by the company’s multimodal data library. This research milestone includes... Read more
MALVERN, Pa., July 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that updated policies from BlueCross BlueShield (BCBS) of Michigan and Cambia Health Solutions will broaden access to TMS (transcranial magnetic stimulation) by expanding the eligible age range to 15 years and older.... Read more
Express Genes enable faster turnaround times
Twist Express Antibodies, CHO starting at 13 business days
Twist Express Antibodies, HEK293 starting at 10 business days SOUTH SAN FRANCISCO, Calif. / Jul 10, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its high-throughput antibody portfolio with the... Read more
Accessible, highly scalable single-cell technology expands Illumina's multiomics capabilities SAN DIEGO, July 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that effective today it has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology.
"The addition of Fluent BioSciences to Illumina will provide significant and new... Read more
SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a second patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.
U.S. patent no. 12,024,749, entitled “Combinatorial DNA Screening,” covers Myriad’s groundbreaking... Read more
Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics SALT LAKE CITY, July 9, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication in Diagnostics, an international, peer-reviewed, open... Read more
NGS-verified synthetic control covers 99.9% of HA and NA genome regions SOUTH SAN FRANCISCO, Calif. / Jul 09, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its growing portfolio of synthetic viral controls with the launch of a synthetic RNA control for H5N1 Influenza A, which is one of the causes... Read more
On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration study ReconAAsense
A recent clinical analysis of this new configuration demonstrates sensitivity for colorectal cancer of 97% and 88% for advanced adenomas, with specificity of 93% BERKELEY, Calif. and MAINZ, Germany, July 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.... Read more
Ideally Suited for Satellite and Independent Labs, the new DxC 500i Analyzer Offers Flexibility, Scalability and Data Commutability with Extensive Chemistry and Immunoassay Assay Menu
The New DxC 500i Analyzer Incorporates Recently Introduced DxC 500 AU Chemistry Analyzer Technology with Six Sigma Performance BREA, Calif., July 9, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today introduces the new DxC 500i Clinical Analyzer*,... Read more
AUSTIN, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has closed its previously announced private placement for the issuance and sale of shares of the Company’s common stock and accompanying warrants to purchase an equal number of shares for gross proceeds... Read more
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 17,513,136 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $0.571 per share of common stock (or per common stock equivalent in lieu thereof). Additionally, in a concurrent private... Read more
CHICAGO / Jul 08, 2024 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company’s PurISTSM algorithmic test has received a proprietary laboratory analysis (PLA) code from the American Medical Association (AMA). The new code will be effective on October 1, 2024. The PurISTSM PLA code is the first common procedural terminology (CPT) code created to describe an algorithm-only analysis from... Read more